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Abstract
Background Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in 
triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance 
being achievable using a software tool. We examined agreement between breast pathologists across Europe scoring sTILs 
on H&E-stained sections without software, an approach that is easily applied in clinical practice. The association between 
sTILs and response to anthracycline-taxane NACT was also examined.
Methodology Pathologists from the European Working Group for Breast Screening Pathology scored sTILs in 84 slides from 
75 TNBCs using the immune-oncology biomarker working group guidance in two circulations. There were 16 participants 
in the first and 19 in the second circulation.
Results Moderate agreement was achieved for absolute sTILs scores (intraclass correlation coefficient (ICC) = 0.683, 95% 
CI 0.601–0.767, p-value < 0.001). Agreement was less when a 25% threshold was used (ICC 0.509, 95% CI 0.416–0.614, 
p-value < 0.001) and for lymphocyte predominant breast cancer (LPBC) (ICC 0.504, 95% CI 0.412–0.610, p-value < 0.001). 
Intra-observer agreement was strong for absolute sTIL values (Spearman ρ = 0.727); fair for sTILs ≥ 25% (κ = 0.53) and for 
LPBC (κ = 0.49), but poor for sTILs as 10% increments (κ = 0.24). Increasing sTILs was significantly associated with an 
increased likelihood of a pathological complete response (pCR) on multivariable analysis.
Conclusion Increasing sTILs in TNBCs improves the likelihood of a pCR. However, inter-observer agreement is such that 
H&E-based assessment is not sufficiently reproducible for clinical application. Other methodologies should be explored, 
but may be at the cost of ease of application.
Keywords Triple-negative breast cancer · Stromal tumour infiltrating lymphocytes · sTILs · Neoadjuvant chemotherapy · 
Inter-observer agreement · Pathological complete response
Background
The role of the immune system in the pathogenesis and 
clinical course of cancer is well established [1, 2] and has 
received renewed attention with the success of immuno-
therapies for several solid organ cancers such as melanoma 
and lung cancer. The assessment of tumour infiltrating 
lymphocytes (TILs) within a tumour has been used as a sur-
rogate measure of the immune response and several studies 
from the 1980s onwards have reported on the prognostic role 
of TILs in a variety of different organ systems [3–5]. Breast 
cancer has historically been regarded as a non-immunogenic 
tumour although a dense lymphoid infiltrate has long been 
observed in the rare medullary subtype [6], which is associ-
ated with a favourable outcome despite its otherwise high-
grade morphological features.
The stromal TIL (sTIL) component in breast cancer has 
been examined in a number of recent clinical studies and 
a prognostic role has been most consistently observed in 
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triple-negative breast cancer (TNBC) and HER2-positive 
cancers compared to other subtypes in both the adjuvant and 
neo-adjuvant setting [7–16]. In two adjuvant series of TNBCs, 
each 10% incremental increase in sTILs was associated with a 
14–19% reduction in risk for recurrence or death [13, 15]. sTIL 
evaluation was included as a secondary endpoint of the Gepar-
sixto trial and, similarly, incremental increases of sTILs were 
positively associated with a pathological complete response 
(pCR) in TNBC patients. In that study, tumours with a dense 
sTIL component, termed lymphocyte predominant breast can-
cer (LPBC), were associated with the highest pCR rate of 74% 
in patients who received carboplatin [7]. LPBCs, whilst not 
representing a specific subtype, have sTILs occupying over 50 
or 60% of the stroma and are uncommon amongst breast can-
cers [7, 9–13, 17]. Gene expression-based analysis of TNBC 
also shows that the TIL component in TNBCs is highly corre-
lated with an immune-rich expression profile that is favourably 
prognostic for relapse-free survival [18].
In order for the potential of a biomarker to be realised in 
clinical practice, it must meet standards for analytic validity 
in terms of the reliability, accuracy and reproducibility of 
the assay. In breast cancer, sTILs are most commonly scored 
on haematoxylin and eosin (H&E)-stained tumour sections. 
Reports of the reproducibility for this methodology vary 
from moderate to excellent [7, 10, 13–15, 17, 19]. In 2015, 
an international immuno-oncology biomarker working group 
produced guidance aimed at standardising sTILs reporting in 
breast cancer [19]; and subsequently reported very high inter-
observer agreement in a large ring study when this guidance 
was combined with an interactive software tool [20].
The aim of our multi-institutional study was to evaluate 
the reproducibility between experienced breast pathologists 
across Europe for scoring sTILs in TNBCs in routine prac-
tice. Our assessment of sTILs was confined to light micros-
copy using the guidance of the immuno-oncology biomarker 
working group on the basis that this methodology is simple 
to perform and could be easily applied in routine practice; 
the software tool was not used because this would add a level 
of complexity that would make it more difficult to roll out in 
clinical practice. The case series was limited to TNBCs for 
two reasons: there is consistent evidence supporting a prog-
nostic and predictive association for sTILs in this subtype, 
and because any differences between subtypes would not 
then be a cause of variation. As a secondary endpoint, the 
association between sTILs and the likelihood of attaining a 
pCR in TNBC was examined.
Materials and methods
The series comprised 75 consecutive TNBCs diagnosed in 
72 patients in a symptomatic breast service of a single ter-
tiary referral centre between 2004 and 2015 (Table 1). All 
but one patient received NACT. Three of the 72 patients had 
multiple synchronous TNBCs. Nine patients had more than 
one core biopsy taken from the same tumour and these addi-
tional biopsies were included to evaluate intratumoural het-
erogeneity. A representative H&E-stained section of the 84 
needle core biopsies (NCBs) from 75 tumours was selected 
and slides were scanned using an Olympus VS120 slide 
scanner. The digitised slides were anonymised and were 
uploaded to the PathXL online repository. pCR breast was 
defined as ypT0/is and pCR breast/axilla as ypT0/isN0 [21].
Table 1  Characteristics of the series (75 TNBCs in 72 patients)
a Reference [21]; n number, NACT neoadjuvant chemotherapy, pCR 
pathological complete response
Parameter Total n n %
Patient age (years)
 Median (range) 72 48 (24–73)
Tumour type 75
 Ductal (NST) 69 92
 Metaplastic 2 3
 Medullary-like 4 5
Tumour grade 75
 1 0 0
 2 20 27
 3 55 73
NACT 71
 Anthracycline and taxane 41 58
 Anthracycline, taxane, and 
carboplatin
28 39
 Unknown regimen 2 3
No NACT 1
ypTa 71
 Is 7 10
 0 30 42
 1 19 27
 2 7 10
 3 3 4
 4 5 7
ypNa 71
 X 1 1
 0 50 70
 1 7 10
 2 9 13
 3 4 6
pCR (Breast) 71
 pCR 37 52
 Non-pCR 34 48
pCR (breast and axilla) 71
 pCR 33 46
 Non-pCR 38 54
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The study consisted of two circulations. In the first cir-
culation, an email with instructions for the study was sent 
to 35 consultant pathologists who were members of the 
European Working Group for Breast Screening Pathology 
(EWG-BSP). The email included the review and the online 
tutorial from the immuno-oncology biomarker working 
group [19], links to the digitised slides, and a MS Excel 
template. Participants were asked to read the tutorial and the 
review before scoring sTILs in each slide and to record the 
absolute percentage of sTILs for each slide in the Excel tem-
plate provided, which was then returned by the individual 
pathologists to the organising pathologist. Participants were 
also asked to record the length of time taken to complete 
the exercise.
After the first circulation, an independent pathologist, 
who was not part of the inter-observer study, reviewed those 
digital slides for which there was a noticeable variance in 
scores and noted the features pertinent to these cases e.g., 
necrosis, difficult boundary, tumour heterogeneity. The 84 
digitised slides were relabelled and reordered at random on 
the PathXL online repository. 4 months after the completion 
of the first circulation, an email that contained links to the 
re-ordered slides, the TILWG tutorial and an Excel template 
was circulated to members of the EWG-BSP. The email for 
this second circulation highlighted the specific guidance 
in the working group tutorial that pertained to those fea-
tures in the slides for which there was most disagreement in 
sTIL scores in the first circulation. Participants were asked 
to review the working group tutorial again and then record 
the absolute percentage of sTILs for each case in the Excel 
template and to return it to the organiser.
Slide selection, scanning and anonymisation were per-
formed by a senior technician and an independent patholo-
gist, neither of whom participated in the inter-observer 
study. All participating pathologists were blinded to the 
scores of other pathologists.
Statistical analysis
The relationships between the pathologists’ scores in the differ-
ent circulations and between each other were assessed as con-
tinuous variables (raw scores); as increments of ten percent; 
and as dichotomous categorical variables using a threshold of 
≥ 25 and of ≥ 50%, the latter defined as LPBC. The intraclass 
correlation coefficient (ICC) was used to assess how closely 
the measurements of sTILs by different pathologists resembled 
each other for each slide [22, 23]. The two-way mixed single 
measures figure was used as it reflects the values for a single 
typical rater. Spearman’s correlation coefficient (ρ) was used 
to measure the strength of the relationship between scores in 
circulation one and circulation two for each individual patholo-
gist for the raw sTIL scores that were given. Cohen’s kappa 
statistic (κ) was used to measure the strength of association 
between circulation one and circulation two scores for each 
individual pathologist for the sTILs as a categorical variable. 
Univariate and multivariate Logistic regression analysis was 
used to calculate odds ratio (OR) and 95% confidence intervals 
(CI) to adjust for prognostic variables. The p-values reported 
were two tailed and a p-value of less than 0.05 was consid-
ered statistically significant. Pearson χ2 testing was also used 
to assess the association between sTILs categories and pCR. 
The sTIL results were collated in Microsoft Excel and were 
subsequently analysed in SPSS 24 and Stata/IC (v14.0).
Results
Sixteen pathologists participated in the first circulation; 
nineteen participated in the second circulation, compris-
ing all sixteen pathologists who partook in the first circula-
tion and an additional three pathologists. The average time 
taken by participants to score sTILs in each slide was 4 min 
(median 3 min; range 1–10 min).
Inter‑observer agreement
The distribution of sTIL scores given by each of the 16 
pathologists who participated in both circulations is shown 
in Fig. 1 and the distribution of sTIL scores recorded for 
all 84 slides is shown in Fig. 2. In circulation 1, the two-
way mixed single measures ICC indicated fair agreement 
for absolute sTIL scores (ICC 0.595, 95% CI 0.517–0.679, 
p-value < 0.001) and for the sTILs ≥ 25% (ICC 0.437, 95% 
CI 0.356–0.531, p-value < 0.001) and for the LPBC cat-
egory (ICC 0.415, 95% CI 0.336–0.508, p-value < 0.001). 
Assessing agreement between just the original 16 partici-
pants in circulation 2, the single measures ICC increased for 
the absolute sTIL scores (ICC 0.683, 95% CI 0.601–0.767, 
p-value < 0.001) reflecting good agreement but agreement 
remained fair for both the sTIL ≥ 25% category (ICC 0.509, 
95% CI 0.416–0.614, p-value < 0.001) and for the LPBC 
group (ICC 0.504, 95% CI 0.412–0.610, p-value < 0.001).
When data from the 19 pathologists participating in 
circulation 2 was evaluated, the single measures ICC for 
the absolute sTIL scores was slightly less than that for the 
original 16 participants (ICC 0.660, 95% CI 0.577–0.747, 
p-value < 0.001); agreement was fair for sTILs ≥ 25% (ICC 
0.501, 95% CI 0.411–0.606, p-value < 0.001) and also for 
LPBC (ICC 0.481, 95% CI 0.391–0.588, p-value < 0.001).
Intra‑observer agreement
The intra-observer agreement for the original 16 patholo-
gists who partook in both circulations ranged from weak to 
very strong correlation for absolute sTIL values (Spearman 
ρ = 0.314 to 0.970; p-values range from < 0.001 to 0.015) 
4 Breast Cancer Research and Treatment (2018) 171:1–9
1 3
with a strong average correlation (Spearman ρ = 0.727). 
The lowest intra-observer agreement for one pathologist 
(Spearman ρ = 0.314, p-value = 0.015) reflected a move 
from poor agreement between this pathologist’s scores 
and those of the other participants in the first circulation 
(average inter-item correlation = 0.356) to strong agree-
ment in the second circulation average inter-item corre-
lation = 0.740. Overall intra-observer agreement was fair 
using the 25% threshold (κ = 0.53; range 0.158–0.947) 
and for the LPBC category (κ = 0.49; range 0.021–0.868) 
but agreement was poor for sTILs as 10% increments 
(κ = 0.24; range 0.069–0.545).
Features associated with poor agreement in sTIL 
scores
An independent pathologist selected the slides for which 
there was greatest inter-observer disagreement in sTIL 
scores on the basis of a standard deviation for absolute scores 
in the top 25%. The features that could explain this varia-
tion were intra-tumoural heterogeneity of sTILs (n = 11), 
necrosis (n = 5), fragmentation of the biopsy (n = 4), diffi-
culties delineating the tumour boarder (n = 4), low (n = 3) 
and high (n = 2) tumour cellularity; some of these features 
co-existed in the same case. When sTIL scores for differ-
ent biopsies from the same tumour were examined (n = 9), 
there was overall moderate agreement (Spearman ρ = 0.511) 
that was weak in three cases (lowest Spearman ρ = 0.276, 
p-value = 0.268).
Association between sTILs and response to NACT 
For the 72 patients, the median sTIL score was 20% (range 
1–80%) in circulation 1 and 15% (range 1–80%) in circula-
tion 2. The distribution of sTIL categories across the 72 
patients is shown in Table 2. The median sTIL score for each 
case from circulation 2 was used to examine the association 
between sTILs and response to NACT. Increasing sTILs was 
paralleled by an increased likelihood of both pCR breast and 
pCR breast/axilla by univariate and multivariable analysis 
(Table 3). Increasing 10% increments of sTILs improved 
the likelihood of both a pCR breast and pCR breast/axilla 
by over 40% on univariate analysis (p-value = 0.020 and 
p-value = 0.022, respectively). LPBC was associated with 
the greatest likelihood of a pCR breast and pCR breast/axilla 
(OR 9.1, 95% CI 1.07–77.2, p-value = 0.043; OR 11.8, 95% 
CI 1.39–100.6, p-value = 0.024 respectively), with the caveat 
that there were only nine LPBCs and a very wide 95% CI 
was observed. By multivariable analysis, increasing 10% 
increments of sTILs was an independent predictor of both 
pCR endpoints when adjusted for age at diagnosis, tumour 
grade and tumour type. Again, the magnitude of the asso-
ciation between sTILs and pCR on multivariable analysis 
was greatest for LPBC and significant for pCR breast/axilla. 
LPBC was associated with a higher rate of pCR breast and 
breast/axilla (both 89%; n = 8) than non-LPBC (47%; n = 29; 
Pearson χ2 5.59. p = 0.018 and 40% (n = 25); Pearson χ2 7.45 
p-value = 0.006, respectively).
Discussion
sTILs have emerged as a potential prognostic and predic-
tive marker in TNBC in the adjuvant and neoadjuvant set-
ting. The consistency of scoring sTILs varies with excellent 
reproducibility reported when a software tool is used along 
Fig. 1  Distribution of sTILs scores given by each of the 16 participat-
ing pathologists for the 84 slides in circulation 1 (a) and in circula-
tion 2 (b). There was greater variation in the range of scores given 
by the 16 pathologists in circulation 1 than in circulation 2 and the 
range of scores given by pathologists changed between the two circu-
lations. Pathologist 1 gave a narrow range of scores relative to other 
participants in circulation 1 and gave a wider range in circulation 2 
that was more in line with that of other participants; the converse was 
observed for pathologist 11. The range of scores given by pathologist 
10 was wide relative to others in both circulations. The distribution of 
scores given by pathologists 14, 15, and 16 converged to become very 
similar in circulation 2
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with guidance from an expert group [19]. In our study, the 
reproducibility of sTILs assessment in TNBC was examined 
using this guidance but without the software tool in order to 
examine reproducibility of a methodology that could be eas-
ily applied in routine practice. Our data affirm the predictive 
importance of sTILs in the neoadjuvant setting whereby 
increasing levels of sTILs are associated with increased 
odds of a pCR following treatment with anthracycline-based 
NACT. However, there was only moderate agreement at best 
between experienced pathologists for scoring sTILs.
The distribution of sTIL scores in our series was similar 
to that reported by others. The median sTIL value of 15% 
(range 1–80%) in circulation 2 is in line with other reports 
of a median of 15–23% in TNBC (9,11,12,14,15,17) and 
higher than that observed by some (13). LPBC was observed 
in 12% of cases, which was within the range of 4.4–28% 
noted by others in TNBCs [7, 9–13, 17]. Increasing sTILs 
was paralleled by an increased likelihood of a pCR on both 
univariate and multivariable analysis. Each 10% increase in 
sTILs improved the likelihood of a pCR by over 40%, which 
is higher than 15–23% described by others [7, 9, 11–15]. 
Although the number of LPBCs was small, our data suggest 
that the predictive relevance of sTILs may be greatest for 
these tumours. This is consistent with data pertaining to the 
Fig. 2  Distribution of sTIL scores for all slides in circulation 1 (a) 
and in circulation 2 (b). The distribution of sTIL scores was less 
heterogeneous in circulation 2 than in circulation 1. In circulation 
2, there were fewer outlier scores and there was a narrow range of 
scores for those cases with a low sTIL population (sTILs < 20%) indi-
cating a better level of agreement for these cases
Table 2  Distribution of sTIL categories in 72 cases of TNBC
sTILs sTILs
Binary categories n (%) 10% increments n (%)
< 10% 34 (47) 1–10 34 (47)
≥ 10% 38 (53) 11–20 16 (22)
< 25% 50 (69) 21–30 7 (10)
≥ 25 22 (31) 31–40 3 (4)
Non-LPBC 63 (88) 41–50 4 (6)
LPBC 9 (12) 51–60 6 (8)
61–70 1 (1)
71–80 1 (1)
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TNBC subset of the Geparsixto study, in which LPBC was 
associated with the greatest increase in likelihood of pCR 
(OR 2.17. CI 1.27–3.73, p-value = 0.05) [7].
Despite the strong favourable association between sTILs 
and response to NACT, the inter-observer agreement in our 
study suggests that sTIL evaluation using this methodology 
is not sufficiently reproducible for application in TNBCs 
in routine practice. Inter-observer agreement for the abso-
lute percentage of sTILs was only moderately reproducible, 
reflected by an ICC of 0.683 with a lower limit of the 95% 
CI of 0.601. Higher levels of agreement for absolute sTIL 
values are reported by others but in studies involving only 
two or three pathologists with recorded ICC values of 0.92 
[7] and 0.97 [17]; 85% agreement [13]; and strong correla-
tion [14]. However, in studies involving more participants, 
reproducibility was comparable to that achieved in this work 
with an ICC value of 0.62 between four pathologists [24]; 
and an ICC of 0.71 in a ring study with 32 pathologists [20]. 
Both our study and the latter ring study [20] included a large 
number of participants and scored sTILs on full face sec-
tions of pre-treatment NCBs. Case mix and selection differed 
between the studies in that the ring study included cases 
from the Geparsixto trial of both TNBCs and HER2-positive 
tumours that were selected to ensure equal representation of 
tumours with different levels of sTILs. Our cases comprised 
consecutive TNBC biopsies from routine practice with no 
pre-selection criteria other than sufficient tumour for diag-
nosis. Thus, the slightly lower level of reproducibility for 
absolute sTIL values reported here may be more reflective 
of what is achievable in routine practice for TNBCs than that 
reported in the ring study. Despite the recommendation to 
score sTILs as a continuous variable [20], and good repro-
ducibility for scoring absolute sTIL values, the clinical util-
ity of the absolute percentage of sTILs is uncertain and has 
only a negligible effect on response to NACT. In contrast, 
10% incremental increases in sTILs are consistently associ-
ated with response to NACT but the utility of this measure 
is likely to be confounded by the poor intra-observer agree-
ment that we observed (κ = 0.24).
Denkert et al. reported excellent reproducibility when 
an interactive software tool was used to aid sTILs assess-
ment [20]. This was achieved for absolute (ICC 0.89) and 
for categorical measures in a cohort pre-selected to include 
equal numbers of cases with low, intermediate and high sTIL 
levels. These data are very promising and the software has 
now become accessible on line (http://www.tilsi nbrea stcan 
cer.org). The software gives the scorer integrated feedback 
by showing pre-calibrated reference images against which 
an image from a case is assessed. However, this approach 
increases the complexity of the evaluation process and the 
time taken; the user is required to create and upload three 
high-power static images from each case to generate a sTIL 
score. In our study, even without this step, the median time 
taken to score each slide was 4 min, which is not insignifi-
cant in the context of a busy routine practice; others report a 
time of between three and nine minutes to score a case using 
the working group guidance [25]. This is significantly longer 
than the time taken to score other biomarkers in breast can-
cer e.g., oestrogen or progesterone receptor and HER2, 
where estimates of positivity are given around pre-defined 
thresholds.
Some of the features that we observed in cases with the 
greatest variation in sTIL scores were highlighted by the 
expert group i.e., necrosis, difficulty delineating the boarder 
[19]; others were not e.g., fragmentation of the core and 
tumour cellularity. Many of these features are not uncom-
mon in TNBC biopsies and, consequently, may hamper 
attempts to improve reproducibility of scoring in this sub-
type. Intra-tumoural heterogeneity was seen most often and 
we observed only moderate agreement (ranging from weak 
to strong) between sTIL scores in paired biopsies from the 
same tumour. It will be difficult to mitigate the effect of 
Table 3  Logistic regression of the association between sTILs and 
achieving a pCR
a Adjusted for age at diagnosis, tumour grade, tumour type
Logistic regression with pCR = 1; non-pCR = 0
OR(pCR) 95% CI P value
Univariate logistic regression analysis
 pCR Breast
  sTILs Absolute % 1.04 1.01–1.08 0.010
  sTILs 10% increments 1.45 1.06–1.98 0.020
  sTILs > 10% 2.64 1.01–6.89 0.048
  sTILs ≥ 25% 3.56 1.18–10.64 0.023
  LPBC 9.10 1.07–77.2 0.043
 pCR breast and axilla
  sTILs Absolute % 1.04 1.01–1.07 0.013
  sTILs 10% increments 1.41 1.05–1.88 0.022
  sTILs > 10% 2.16 0.83–5.61 0.114
  sTILs ≥ 25% 2.76 0.97–7.83 0.056
  LPBC 11.84 1.39–100.6 0.024
Multivariable logistic regression analysisa
 pCR breast
  sTILs absolute % 1.05 1.01–1.09 0.016
  sTILs 10% increments 1.49 1.03–2.15 0.035
  sTILs > 10% 2.08 0.71–6.12 0.185
  sTILs ≥ 25% 3.93 1.01–13.95 0.034
  LPBC 8.29 0.81–84.55 0.074
 pCR breast and axilla
  sTILs absolute % 1.04 1.01–1.07 0.013
  sTILs 10% increments 1.41 1.05–1.88 0.022
  sTILs > 10% 1.64 0.54–4.99 0.387
  sTILs ≥ 25% 3.07 0.88–10.67 0.077
  LPBC 17.6 1.19–259.35 0.037
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heterogeneity on the analytic and clinical validity of sTILs 
in TNBCs because of the potential for sampling bias aris-
ing from the reliance on NCBs in the neoadjuvant setting. 
The working group guidance recommends giving an average 
sTIL score for a case; however, there have been no formal 
studies examining either the effect of heterogeneity on repro-
ducibility or the relative clinical importance of a sTIL score 
derived from the average sTIL population, the hot-spots or 
the area with the lowest sTILs.
Our study has limitations. The number of cases was small 
and, as in many studies, the small number of LPBCs ham-
pered the interpretation of their significance. We restricted 
our analysis to TNBC, in which the potential clinical rel-
evance of sTILs has been shown most consistently, and our 
data may not be pertinent to other subtypes of breast can-
cer. For example, in a previous study on 454 breast cancers 
treated with NACT, we showed that the presence or absence 
of sTILs, with a cut off of 1%, significantly impacted on 
response to treatment in the Luminal B oestrogen receptor-
positive/HER2-negative subtype [26]. Nonetheless, our 
series is an accurate reflection of TNBCs that are diagnosed 
in routine practice with no pre-selection applied. Participat-
ing pathologists did not receive formal training in scoring 
sTILs in the interval between the two circulations. Formal 
training of pathologists is emphasised to improve the con-
sistency of reporting many of the newer predictive immuno-
histochemical biomarkers in other cancer types [27] and it 
could be argued that training could have improved consist-
ency for scoring sTILs in this work. In our second circu-
lation, we observed slightly better agreement between the 
sixteen pathologists who had already undertaken the exer-
cise in the first circulation (ICC 0.683, 95% CI 0.601–0.767, 
p < 0.001) than we observed when scores from three new 
participants were included (ICC 0.660, 95% CI 0.577–0.747, 
p < 0.001). Notwithstanding, the participants were experi-
enced breast pathologists from across Europe that would 
be representative of international best practice. Finally, the 
aim of our study was to assess concordance in measuring 
the whole sTIL population; we did not examine subpopula-
tions of lymphoid cells which may provide a more functional 
assessment of the immune infiltrate [28–31].
In conclusion, our data affirm the predictive significance 
of sTILs with respect to pCR in TNBC. Quantification of 
sTILs by light microscopy is simple and would be suitable 
for widespread clinical application; however, our data show 
considerable inter- and intra-observer variability between 
experienced breast pathologists in the assessment of sTILs 
using the immuno-oncology biomarker working group guid-
ance alone. Tumour heterogeneity contributed to reproduc-
ibility issues. Other methodologies may improve the consist-
ency for scoring sTILs and should continue to be explored. 
The software tool of the immuno-oncology biomarker work-
ing group has the potential to improve standardisation but 
at the expense of decreased ease of use. Further studies will 
need to validate this tool for scoring sTILs in cases from 
routine practice, without the pre-selection of cases applied 
in the ring study (21), and to determine if can overcome the 
effect on heterogeneity on reproducibility. Formal studies 
evaluating the clinical importance of sTIL heterogeneity 
with data to support guidance on how heterogeneous cases 
should be scored is required. Methodological studies aimed 
at improving the consistency of reporting sTILs may need 
to be designed with specific tumour subtypes and clinical 
endpoints in mind.
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